For example, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant cardiovascular risk reduction in patients with obesity and type 2 diabetes, independent of their effects on lipid levels [32,33]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.